Publication details
Prognostic and predictive markers for perineural and bone invasion of oral squamous cell carcinoma
| Authors | |
|---|---|
| Year of publication | 2019 |
| Type | Article in Periodical |
| Magazine / Source | Biomedical Papers |
| MU Faculty or unit | |
| Citation | |
| Web | https://biomed.papers.upol.cz/artkey/bio-201904-0003_prognostic-and-predictive-markers-for-perineural-and-bone-invasion-of-oral-squamous-cell-carcinoma.php |
| Doi | http://dx.doi.org/10.5507/bp.2019.032 |
| Keywords | squamous cell carcinoma; oral cavity and oropharynx; bone invasion; perineural invasion |
| Attached files | |
| Description | Oral squamous cell carcinoma (OSCC) is a growing problem worldwide. Several biological and molecular criteria have been established for making a prognosis of OSCC. One of the most important factors affecting the risk of tumor recurrence and overall prognosis is perineural invasion and bone invasion. Perineural invasion is defined as a tumor spreading and the ability of tumor cells to penetrate around or through the nerve tissue. Perineural invasion can cause the tumor to spread to distant areas from the primary tumor location. One possible explanation for this is the formation of microenvironment in the perineural space which may contain cellular factors that act on both nerve tissue and some types of tumor tissues. Bone invasion by OSCC has major implications for tumor staging, choice of treatment, outcome and quality of life. Oral SCCs invade the mandibular or maxillary bone through an erosive, infiltrative or mixed pattern that correlates with clinical behavior. Bone resorption by osteoclasts is an important step in the process of bone invasion by oral SCCs. Some cytokines (e.g. TNFa and PTHrP) lead to receptor activator of NF-kB ligand (RANKL) expression or osteoprotegerin (OPG) suppression in oral SCC cells and in cancer stromal cells to induce osteoclastogenesis. Oral SCCs provide a suitable microenvironment for osteoclastogenesis to regulate the balance of RANKL and OPG. A more molecular-based clinical staging and tailor-made therapy would benefit patients with bone invasion by OSCC. |